Trial reportBMC urology2018
The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study.
Trial report in BMC urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- The impact of pharmacotherapy on sexual function in female patients being treated for idiopathic overactive bladder: a systematic review.BMC women's health · 2024Pooled it
- Impact of intravesical onabotulinumtoxinA (Botox) on sexual function in patients with overactive bladder syndrome: a systematic review and meta-analysis.International urogynecology journal · 2022Pooled it
- STOMp: sexual function trial of overactive bladder medication.Sexual medicine · 2023Article
- Is coital incontinence a manifestation of urodynamic stress incontinence or detrusor overactivity?International urogynecology journal · 2022Article
- Quality of Life, Psychological Wellbeing, and Sexuality in Women with Urinary Incontinence-Where Are We Now: A Narrative Review.Medicina (Kaunas, Lithuania) · 2022Review
- Overactive Bladder Syndrome Treatments and Their Effect on Female Sexual Function: A Review.Sexual medicine · 2020Review
- The effect of overactive bladder treatment with anticholinergics on female sexual function in women: a prospective observational study.International urology and nephrology · 2019Observational
Corrections and comments
- Commented on by
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundΑim of the study was to determine the effect of mirabegron, used for overactive bladder (OAB) treatment, on female sexual function.
methodsEighty five sexually active women suffering from overactive bladder were prospectively enrolled in this study. Females were divided into two groups. In Group A (control), 48 patients received no treatment and in Group B, 37 patients received mirabegron 50 mg/daily for 3 months. Patients were evaluated with FSFI-Gr at the beginning of the study and again after a period of 3 months.
resultsIn Group B, there was a significant increase post-treatment compared to baseline (p < 0.001) in total FSFI (20.3 (3.8) to 26.6 (4.2)) and all domains (desire: 3.0 (1.2) to 4.8 (1.2)), arousal: 3.0 (0.8) to 4.8 (0.9), lubrication: 3.9 (1.1) to 4.8 (1.2), orgasm: 3.6 (0.8) to 4.8 (1.0), satisfaction: 3.2 (0.4) to 4.0 (0.8) and pain: 3.2 (0.8) to 4.4 (1.2)). In Group A, there were no statistically significant changes in pre- and post-observation values.
conclusionsThis study is one of the few demonstrating that management of OAB with mirabegron improves female sexual function.
trial registrationTRN ISRCTN17199301 , 20/10/2017, retrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.